Telomir Pharmaceuticals (NASDAQ: TELO) announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that Telomir-Zn, the company’s lead small-molecule therapeutic, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The findings, published online and available at this link, show that Telomir-Zn reduced oxidative stress, lowered hepatic copper burden, and improved liver function markers, providing strong evidence of biological activity in this rare genetic disorder.
Wilson’s disease is characterized by copper accumulation in the liver and brain, leading to oxidative damage and progressive organ failure. The preclinical study evaluated Telomir-Zn’s effects in a well-established animal model, measuring survival rates, copper levels, and markers of liver health. Results indicated that treated animals experienced significantly improved survival compared to controls, along with decreased hepatic copper content and normalization of liver enzymes. These outcomes suggest Telomir-Zn may address underlying disease mechanisms by modulating intracellular metal homeostasis and redox balance.
This publication expands the scientific validation of Telomir-Zn, which is already being advanced toward a Phase 1/2 clinical trial for triple-negative breast cancer. The company’s platform focuses on targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative diseases. According to the press release, the Wilson’s disease findings support the molecule’s broader therapeutic potential beyond oncology.
Telomir Pharmaceuticals, a preclinical-stage biotechnology company, develops small-molecule therapeutics designed to modulate intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The company’s newsroom, accessible at this link, provides updates on ongoing research and development activities.
The publication in a peer-reviewed journal adds credibility to the preclinical data and positions Telomir-Zn as a potential treatment for Wilson’s disease, a condition with limited therapeutic options. The reduction in oxidative stress and copper burden highlights the compound’s mechanism of action, which may also be relevant to other diseases characterized by metal dyshomeostasis and oxidative damage. As Telomir Pharmaceuticals prepares for clinical trials, these results provide a foundation for further investigation into Telomir-Zn’s applications in rare genetic disorders.
